Sanofi Pasteur is the first vaccine manufacturer in the world to roll
out innovative GS1 bar codes on commercially available vaccine products
TORONTO, Feb. 7, 2012 /CNW Telbec/ - Sanofi Pasteur, the vaccines
division of Sanofi (EURONEXT: SAN and NYSE: SNY), is pleased to
announce that it is adding the GS1 2D DataMatrix bar code symbology to
its vaccines manufactured and sold in Canada. This includes Canada's
only billion-dollar biotech product - the world's only five-component
acellular pertussis (whooping cough) combination vaccines (Pediacel®, Quadracel®, Adacel®, Adacel®-Polio). Sanofi Pasteur is the first vaccine developer and manufacturer
in the world to implement the GS1 bar code system on commercially
available vaccines, a key component of Canada's National Immunization
Strategy. This technology will enable automated entry of vaccine
product, lot number and expiry information into immunization registries
and patient records eliminating data entry errors which are as high as
20% in registries relying on manual input.
"As a leader in our industry, we are committed to adopting innovative
solutions to support Canada's national immunization strategy. The use
of GS1 bar code on products that we manufacture in Canada is one step
towards having more accurate immunization records," stated Mark
Lievonen, President of Sanofi Pasteur Limited. "This is about improving
the healthcare system by easing the burden on our doctors and nurses by
making it easier to compile and view crucial information to ensure safe
vaccine use" concluded Mr. Lievonen.
Canada's National Immunization Strategy (NIS) is a comprehensive
strategy elaborated to meet Canada's immunization needs. It includes:
ensuring access to vaccines, program safety and effectiveness, the
security of vaccine supply, and improving Canada's ability to provide
rapid and effective national interventions in emergency situations.
Immunization traceability is an essential part of the success of this
strategy and a top priority for the Public Health Agency of Canada's
(PHAC) Automated Identification of Vaccines Projects (AIVP).
Sanofi Pasteur is a member of the AIVP Advisory Task Group, a
collaborative effort co-chaired and established by the PHAC that brings
together all stakeholders groups in the area of immunization to support
the use of product identification based on global standards. The GS1
standard will help optimise the tracking and administration of vaccines
at point-of-care by providing complete and accurate information through
a simple bar code scan. With this information, the PHAC will be able to
obtain and track accurate immunization rates for Canadians.
"Canada has been ahead of the curve, working on improving the
identification of vaccines since 1999, and we are finally beginning to
see the fruits of our labour. There are many stakeholders involved and
having everyone on board is crucial for the implementation of global
traceability standards," said Dr. John Spika, Director General, Centre
for Immunization and Respiratory Infectious Diseases (CIRID), PHAC. "We
commend Sanofi Pasteur for their leadership and encourage all other
stakeholders to follow suit to help build accurate and complete
national immunization records for the benefit of public health,"
concluded Dr. Spika.
"Sanofi Pasteur supports the PHAC's objectives and their leadership in
bringing these global standards forward. Accurate and complete
immunization records represent a powerful tool for public health. It is
the only way to really know for which diseases we are properly
immunized against, and for which ones we are not," added Dr. Robert Van
Exan, Director of Immunization Policy, Sanofi Pasteur Limited and
Co-Chair of the AIVP.
About the GS1 Bar Code
The GS1 bar code applied to vaccines will contain variable data,
including the vaccine's unique Global Trade Item Number (GTIN) and its
lot number, making it identifiable worldwide. The GTIN is provided by
GS1 Canada, a not-for-profit organization and member of GS1, the
world's leading supply chain standards organization. This format is
increasingly the bar code of choice because of its ability to provide a
significant amount of information on a small surface while being
resilient to frequent handling.
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs, rare
diseases, consumer healthcare, emerging markets and animal health.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1
billion doses of vaccine each year, making it possible to immunize more
than 500 million people across the globe. A world leader in the vaccine
industry, Sanofi Pasteur offers the broadest range of vaccines
protecting against 20 infectious diseases. The company's heritage, to
create vaccines that protect life, dates back more than a century.
Sanofi Pasteur is the largest company entirely dedicated to vaccines.
Every day, the company invests more than EUR 1 million in research and
development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied
or projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory
authorities, such as the FDA or the EMA, regarding whether and when to
approve any drug, device or biological application that may be filed
for any such product candidates as well as their decisions regarding
labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of
guarantee that the products candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed
under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2010. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Image with caption: "Sanofi Pasteur vaccine with GS1 2D Datamatrix bar code (CNW Group/SANOFI PASTEUR)". Image available at: http://photos.newswire.ca/images/download/20120207_C9764_PHOTO_EN_9672.jpg
SOURCE SANOFI PASTEUR
For further information: